The ‘search for a magic bullet has faded’ in cancer immunotherapy. Here’s what’s next

The two best-selling checkpoint inhibitors — Merck’s Keytruda and Bristol Myers Squibb’s Opdivo — are now approaching their patent cliffs. And the biopharma industry is coming to terms with the fact that it may not be able to repeat its success.

Raccontata daendpoints.news